免疫调节剂在多发性骨髓瘤患者中的治疗进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i3.7534
Abstract
多发性骨髓瘤是一种浆细胞克隆性增殖的血液恶性肿瘤,在血液恶性肿瘤中占第二位。包括蛋白酶体抑制剂、免疫调节剂、单克隆抗体等新药的广泛使用,显著延长了多发性骨髓瘤患者的生存时间。但因几乎所有多发性骨髓瘤患者都会复发,该病目前仍无法治愈。本综述旨在分析沙利度胺、来那度胺和泊马度胺在内的免疫调节剂治疗多发性骨髓瘤的疗效与安全性,为临床更好的应用免疫调节剂提供理论依据。
Keywords
多发性骨髓瘤；免疫调节剂；泊马度胺；复发难治；初诊
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 中国医师协会血液科医师分会,中华医学会血液学分会,黄晓军.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,061(005):480-487.
[2] YANG Y,LI Y,GU H,et al.Emerging agents and regimens for multiple myeloma[J].Hematol Oncol,2020,13(1):150.
[3] DELFORGE M,VLAYEN S,KINT N.Immunomodulators in newly diagnosed multiple myeloma: current and future concepts [J].Expert Review of Hematology,2021,14(4):365-376.
[4] PALUMBO A,FACON T,SONNEVELD P,et al.Thalidomide for treatment of multiple myeloma: 10 years later[J].Blood,2008, 111(8):3968-3977.
[5] SCHÜTZ NP,OCHOA P,DUARTE P,et al.Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosph amide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin Ame rican country. A Retrospective Cohort Study from Grupo Arg entino de Mieloma Múltiple[J].Hematological Oncology,2020,38 (3):363-371.
[6] ŠTORK M,SANDECKÁ V,BOICHUK I,et al.Bortezomib and Tha lidomide Treatment Results in Newly Diagnosed TransplantIneligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up[J].Klinicka Onkologie,2019,32(6):445-452.
[7] DU JS,KUO YC,SHI HY,et al.The Cost-Effectiveness Anal ysis of Transplant-Ineligible Myeloma Patients with Bortezo mib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan[J].Pers Med,2022,12(2):130.
[8] WANG Y,MAN QH,LI C,et al.Clinical efficacy of Thalidomi de combined with PAD Regimen in patients with multiple Myel oma[J].Pak J Med Sci,2023,39(5):1243-1248.
[9] DRUMMOND PLM,SANTOS RMMD,REIS AMM,et al.Real-world effectiveness and safety of multiple myeloma treatments ba sed on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis[J].Cancer Epidemiology,2023,85:102377.
[10] ROSIÑOL L,ORIOL A,RIOS R,et al.Bortezomib, lenalidom ide, and dexamethasone as induction therapy prior to autol ogous transplant in multiple myeloma[J].Blood,2019,134(16): 1337-1345.
[11] JUNG KS,KIM K,KIM HJ,et al.Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Pati ents With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study[J].Clinical Lymphoma Myeloma and Leukemia, 2020,20(2):e97-e104.
[12] SEMERARO M,VACCHELLI E,EGGERMONT A,et al.Trial Wat ch: Lenalidomide-based immunochemotherapy[J].Oncoimmunol ogy,2013,2(11):e26494.
[13] LONIAL S,JACOBUS S,FONSECA R,et al.Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma[J].Clin Oncol,2020,38(11):1126-1137.
[14] KUMAR L,CHELLAPURAM SK,SAHOO R,et al.VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III,randomized study[J].Clinical Lymphoma Myeloma and Leukemia,2019,19(10):e361.
[15] GAY F,MUSTO P,ROTA-SCALABRINI D,et al.Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial[J].The Lancet Oncolo gy,2021,22(12):1705-1720.
[16] CHEN CI,CAO Y,TRUDEL S,et al.An open-label, pharmaco kinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines[J].Leuk Lymphoma,2020,61(8):1860-1868.
[17] DIMOPOULOS MA,CHEN C,SPENCER A,et al.Long-term fol low-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma[J].Leukemia, 2009,23 (11):2147-2152.
[18] JO JC,LEE HS,KIM K,et al.The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP -151study)[J].Ann Hematol,2020,99(2):309-319.
[19] ANANDH U,VASWANI B,GOWRISHANKAR S.Acute Interstiti al Nephritis following Lenalidomide Therapy in a Patient with AL Amyloidosis[J].Indian J Nephrol,2022,32(4):390-391.
[20] DIMOPOULOS M,WEISEL K,VAN DE DONK NWCJ,et al.Pomali domide Plus Low-Dose Dexamethasone in Patients With Relaps ed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial[J].Journal of Clinical Oncology,2018,36 (20):2035-2043.
[21] MCDANIEL JM,PINILLA-IBARZ J,EPLING-BURNETTE PK.Mo lecular action of lenalidomide in lymphocytes and hematolo gicmalignancies[J].Advances in Hematology,2012:1-9.
[22] RICHARDSON PG,ORIOL A,BEKSAC M,et al.Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalido mide(OPTIMISMM):a randomised,open-label,phase 3 trial[J].The Lancet Oncology,2019,20(6):781-794.
[23] SANDECKA V,POUR L,ŠPIČKA I,et al.Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech regist ry data[J].Neoplasma,2022,69(6):1474-1479.
[24] LELEU X,KARLIN L,MACRO M,et al.Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)[J].Blood,2013,122(21):689-689.
[25] DIMOPOULOS M, WEISEL K, MOREAU P,et al.Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previou sly treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse[J].Leukemia,2021,35(6):1722-1731.
[26] SHARPLEY FA,MANWANI R,MAHMOOD S,et al.Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis[J].British Journal of Haematology,2018,183 (4):557-563.
[27] SAJ F, NISHA Y, GANESAN P,et al.Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study[J].Blood,2023,13(1):45.
[28] RADHAKRISHNAN VS,TAMBOLI N,DAS S,et al.BortezomibPomalidomide-Dexamethasone (VPD) As Novel Induction Thera py in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study)[J].Blood,2021,138:2752-2752.
[29] GARDERET L,KUHNOWSKI F,BERGE B,et al.Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma[J].British Journal of Haematol ogy,2023,201(6):1103-1115.
[2] YANG Y,LI Y,GU H,et al.Emerging agents and regimens for multiple myeloma[J].Hematol Oncol,2020,13(1):150.
[3] DELFORGE M,VLAYEN S,KINT N.Immunomodulators in newly diagnosed multiple myeloma: current and future concepts [J].Expert Review of Hematology,2021,14(4):365-376.
[4] PALUMBO A,FACON T,SONNEVELD P,et al.Thalidomide for treatment of multiple myeloma: 10 years later[J].Blood,2008, 111(8):3968-3977.
[5] SCHÜTZ NP,OCHOA P,DUARTE P,et al.Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosph amide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin Ame rican country. A Retrospective Cohort Study from Grupo Arg entino de Mieloma Múltiple[J].Hematological Oncology,2020,38 (3):363-371.
[6] ŠTORK M,SANDECKÁ V,BOICHUK I,et al.Bortezomib and Tha lidomide Treatment Results in Newly Diagnosed TransplantIneligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up[J].Klinicka Onkologie,2019,32(6):445-452.
[7] DU JS,KUO YC,SHI HY,et al.The Cost-Effectiveness Anal ysis of Transplant-Ineligible Myeloma Patients with Bortezo mib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan[J].Pers Med,2022,12(2):130.
[8] WANG Y,MAN QH,LI C,et al.Clinical efficacy of Thalidomi de combined with PAD Regimen in patients with multiple Myel oma[J].Pak J Med Sci,2023,39(5):1243-1248.
[9] DRUMMOND PLM,SANTOS RMMD,REIS AMM,et al.Real-world effectiveness and safety of multiple myeloma treatments ba sed on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis[J].Cancer Epidemiology,2023,85:102377.
[10] ROSIÑOL L,ORIOL A,RIOS R,et al.Bortezomib, lenalidom ide, and dexamethasone as induction therapy prior to autol ogous transplant in multiple myeloma[J].Blood,2019,134(16): 1337-1345.
[11] JUNG KS,KIM K,KIM HJ,et al.Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Pati ents With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study[J].Clinical Lymphoma Myeloma and Leukemia, 2020,20(2):e97-e104.
[12] SEMERARO M,VACCHELLI E,EGGERMONT A,et al.Trial Wat ch: Lenalidomide-based immunochemotherapy[J].Oncoimmunol ogy,2013,2(11):e26494.
[13] LONIAL S,JACOBUS S,FONSECA R,et al.Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma[J].Clin Oncol,2020,38(11):1126-1137.
[14] KUMAR L,CHELLAPURAM SK,SAHOO R,et al.VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III,randomized study[J].Clinical Lymphoma Myeloma and Leukemia,2019,19(10):e361.
[15] GAY F,MUSTO P,ROTA-SCALABRINI D,et al.Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial[J].The Lancet Oncolo gy,2021,22(12):1705-1720.
[16] CHEN CI,CAO Y,TRUDEL S,et al.An open-label, pharmaco kinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines[J].Leuk Lymphoma,2020,61(8):1860-1868.
[17] DIMOPOULOS MA,CHEN C,SPENCER A,et al.Long-term fol low-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma[J].Leukemia, 2009,23 (11):2147-2152.
[18] JO JC,LEE HS,KIM K,et al.The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP -151study)[J].Ann Hematol,2020,99(2):309-319.
[19] ANANDH U,VASWANI B,GOWRISHANKAR S.Acute Interstiti al Nephritis following Lenalidomide Therapy in a Patient with AL Amyloidosis[J].Indian J Nephrol,2022,32(4):390-391.
[20] DIMOPOULOS M,WEISEL K,VAN DE DONK NWCJ,et al.Pomali domide Plus Low-Dose Dexamethasone in Patients With Relaps ed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial[J].Journal of Clinical Oncology,2018,36 (20):2035-2043.
[21] MCDANIEL JM,PINILLA-IBARZ J,EPLING-BURNETTE PK.Mo lecular action of lenalidomide in lymphocytes and hematolo gicmalignancies[J].Advances in Hematology,2012:1-9.
[22] RICHARDSON PG,ORIOL A,BEKSAC M,et al.Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalido mide(OPTIMISMM):a randomised,open-label,phase 3 trial[J].The Lancet Oncology,2019,20(6):781-794.
[23] SANDECKA V,POUR L,ŠPIČKA I,et al.Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech regist ry data[J].Neoplasma,2022,69(6):1474-1479.
[24] LELEU X,KARLIN L,MACRO M,et al.Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)[J].Blood,2013,122(21):689-689.
[25] DIMOPOULOS M, WEISEL K, MOREAU P,et al.Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previou sly treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse[J].Leukemia,2021,35(6):1722-1731.
[26] SHARPLEY FA,MANWANI R,MAHMOOD S,et al.Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis[J].British Journal of Haematology,2018,183 (4):557-563.
[27] SAJ F, NISHA Y, GANESAN P,et al.Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study[J].Blood,2023,13(1):45.
[28] RADHAKRISHNAN VS,TAMBOLI N,DAS S,et al.BortezomibPomalidomide-Dexamethasone (VPD) As Novel Induction Thera py in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study)[J].Blood,2021,138:2752-2752.
[29] GARDERET L,KUHNOWSKI F,BERGE B,et al.Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma[J].British Journal of Haematol ogy,2023,201(6):1103-1115.
Copyright © 2024 李春燕, 陈丹桂, 严红
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License